Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ryukaikon to Meet on Nov. 5 for the First Time One Year after Issuing Emergency Calls
November 3, 2008
- Criteria for Premium for Dispensing Generics Must Be Discussed by Chuikyo Members
November 3, 2008
- BUSINESS NEWS IN BRIEF
November 3, 2008
- Calls by MRs Most Important Factor when Pharmacies Choose Generics
November 3, 2008
- All of the Top Seven Products ARBs in August: Rep Track Survey
November 3, 2008
- Japan, India Fail to Finalize EPA
November 3, 2008
- Stop Press／Kowa Applies for Pitavastatin in US
November 3, 2008
- OPINION／Passion and Principles: Keys to Unlocking Talent
November 3, 2008
- ASKA Obtains Approval for Menoaid Combipatch
November 3, 2008
- Korosho to Review Opinions Received on Online Sale of OTC Drugs
November 3, 2008
- Daiichi Sankyo Responds to Speculation on Status of Prasugrel NDA
November 3, 2008
- Olympus Launches Endo Capsule
November 3, 2008
- PMDA to Increase Staff with Academic Background in Natural Sciences
November 3, 2008
- Korosho to Optimize Approved Doses for 4 Thiazide Diuretics
November 3, 2008
- NEW PRODUCTS
November 3, 2008
- Irribow Drug of Choice for Diarrhea-Predominant IBS
November 3, 2008
- REGULATORY NEWS IN BRIEF
November 3, 2008
- JSHP President Not Ready to Consider Merger with JPA
November 3, 2008
- DSP to Embark on Joint Research with Osaka Univ. in Neuropsychiatry
November 3, 2008
- Number of Pharmacies Totals 52,539
November 3, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…